Gilead Sciences, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 140 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Gilead Sciences, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Gilead Sciences, Inc. - Product Pipeline Review - 2014', provides an overview of the Gilead Sciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Gilead Sciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Gilead Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Gilead Sciences, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Gilead Sciences, Inc.'s pipeline products

Reasons to buy

- Evaluate Gilead Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Gilead Sciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Gilead Sciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Gilead Sciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Gilead Sciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Gilead Sciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Gilead Sciences, Inc. Snapshot 8
Gilead Sciences, Inc. Overview 8
Key Information 8
Key Facts 8
Gilead Sciences, Inc. - Research and Development Overview 9
Key Therapeutic Areas 9
Gilead Sciences, Inc. - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Partnered Products/Combination Treatment Modalities 18
Pipeline Products - Out-Licensed Products 19
Out-Licensed Products/Combination Treatment Modalities 20
Gilead Sciences, Inc. - Pipeline Products Glance 21
Gilead Sciences, Inc. - Late Stage Pipeline Products 21
Pre-Registration Products/Combination Treatment Modalities 21
Phase III Products/Combination Treatment Modalities 22
Gilead Sciences, Inc. - Clinical Stage Pipeline Products 23
Phase II Products/Combination Treatment Modalities 23
Phase I Products/Combination Treatment Modalities 25
Gilead Sciences, Inc. - Early Stage Pipeline Products 26
Preclinical Products/Combination Treatment Modalities 26
Discovery Products/Combination Treatment Modalities 27
Gilead Sciences, Inc. - Drug Profiles 28
(cobicistat + darunavir) 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
(ledipasvir + sofosbuvir) 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
cobicistat 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
elvitegravir 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
idelalisib 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
sofosbuvir 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
tenofovir disoproxil fumarate 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide) 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ambrisentan 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
momelotinib 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
nimotuzumab 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ranolazine ER 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tenofovir alafenamide 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
(darunavir + cobicistat + emtricitabine + tenofovir alafenamide) 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
(ranolazine + dronedarone) 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
(Sofosbuvir + GS-5816) 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GS-4774 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
GS-5806 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
GS-6615 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GS-9256 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GS-9669 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GS-9973 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
regadenoson 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
simtuzumab 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
tegobuvir 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
vedroprevir 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
GS-4997 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
GS-5737 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GS-5745 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
GS-9620 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
GS-9857 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
AB-0045 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
GS-607601 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
GS-8374 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
GS-967 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
GS-563253 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
GS-599220 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecule to Inhibit NS4B Protein for HCV 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules to Inhibit NS3 Protease for Hepatitis C 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Gilead Sciences, Inc. - Pipeline Analysis 86
Gilead Sciences, Inc. - Pipeline Products by Target 86
Gilead Sciences, Inc. - Pipeline Products by Route of Administration 88
Gilead Sciences, Inc. - Pipeline Products by Molecule Type 89
Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action 90
Gilead Sciences, Inc. - Recent Pipeline Updates 92
Gilead Sciences, Inc. - Dormant Projects 123
Gilead Sciences, Inc. - Discontinued Pipeline Products 126
Discontinued Pipeline Product Profiles 126
adefovir dipivoxil 126
ambrisentan 126
aztreonam 127
cicletanine 127
clevudine 127
Darusentan 127
dexelvucitabine 127
emivirine 128
enoximone 128
fentanyl citrate 128
GS-9005 128
GS-9132 128
GS-9667 129
PSI-938 129
tesmilifene hydrochloride 129
Gilead Sciences, Inc. - Company Statement 130
Gilead Sciences, Inc. - Locations And Subsidiaries 134
Head Office 134
Other Locations & Subsidiaries 134
Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 140
Disclaimer 140

List of Tables
Gilead Sciences, Inc., Key Information 8
Gilead Sciences, Inc., Key Facts 8
Gilead Sciences, Inc. - Pipeline by Indication, 2014 11
Gilead Sciences, Inc. - Pipeline by Stage of Development, 2014 14
Gilead Sciences, Inc. - Monotherapy Products in Pipeline, 2014 15
Gilead Sciences, Inc. - Combination Treatment Modalities in Pipeline, 2014 16
Gilead Sciences, Inc. - Partnered Products in Pipeline, 2014 17
Gilead Sciences, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 18
Gilead Sciences, Inc. - Out-Licensed Products in Pipeline, 2014 19
Gilead Sciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 20
Gilead Sciences, Inc. - Pre-Registration, 2014 21
Gilead Sciences, Inc. - Phase III, 2014 22
Gilead Sciences, Inc. - Phase II, 2014 23
Gilead Sciences, Inc. - Phase I, 2014 25
Gilead Sciences, Inc. - Preclinical, 2014 26
Gilead Sciences, Inc. - Discovery, 2014 27
Gilead Sciences, Inc. - Pipeline by Target, 2014 87
Gilead Sciences, Inc. - Pipeline by Route of Administration, 2014 88
Gilead Sciences, Inc. - Pipeline by Molecule Type, 2014 89
Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action, 2014 91
Gilead Sciences, Inc. - Recent Pipeline Updates, 2014 92
Gilead Sciences, Inc. - Dormant Developmental Projects,2014 123
Gilead Sciences, Inc. - Discontinued Pipeline Products, 2014 126
Gilead Sciences, Inc., Other Locations 134
Gilead Sciences, Inc., Subsidiaries 135